Trial Profile
Study to investigate the safety and efficacy extended dose Natalizumab schedules
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 08 Jun 2015 New trial record
- 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.